Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF
Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF
Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF
PDF) Genomic characterization of ependymomas reveals 6q loss as the most common aberration
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
PDF) Genomic characterization of ependymomas reveals 6q loss as the most common aberration
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
PDF) Genomic characterization of ependymomas reveals 6q loss as the most common aberration
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
PDF) Genomic characterization of ependymomas reveals 6q loss as the most common aberration
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Role of mathematical modeling on the optimal control of HIV‐1 pathogenesis | Request PDF
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
PDF) Genomic characterization of ependymomas reveals 6q loss as the most common aberration
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
PDF) Genomic characterization of ependymomas reveals 6q loss as the most common aberration
